| 1 |
34667024 | A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma. | 2022 Jan 1 |
1 |
| 2 |
35192728 | Poloxamer-linked prodrug of a topoisomerase I inhibitor SN22 shows efficacy in models of high-risk neuroblastoma with primary and acquired chemoresistance. | 2022 Mar |
1 |
| 3 |
35197630 | Effective drug combinations in breast, colon and pancreatic cancer cells. | 2022 Mar |
1 |
| 4 |
32743640 | Irinotecan and vandetanib create synergies for treatment of pancreatic cancer patients with concomitant TP53 and KRAS mutations. | 2021 May 20 |
2 |
| 5 |
33869031 | WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma. | 2021 |
1 |
| 6 |
33970400 | The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment. | 2021 Jul |
3 |
| 7 |
34258881 | Mechanistic insights into p53-regulated cytotoxicity of combined entinostat and irinotecan against colorectal cancer cells. | 2021 Dec |
1 |
| 8 |
32084420 | Enhanced proliferation inhibition and apoptosis in glioma cells elicited by combination of irinotecan and imatinib. | 2020 May 5 |
4 |
| 9 |
32502622 | P53 activation suppresses irinotecan metabolite SN-38-induced cell damage in non-malignant but not malignant epithelial colonic cells. | 2020 Sep |
4 |
| 10 |
32961616 | Combined use of irinotecan and p53 activator enhances growth inhibition of mesothelioma cells. | 2020 Nov |
4 |
| 11 |
30898612 | Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals. | 2019 May |
1 |
| 12 |
31056264 | A novel mechanism of irinotecan targeting MDM2 and Bcl-xL. | 2019 Jun 25 |
3 |
| 13 |
31289894 | Functional mismatch repair and inactive p53 drive sensitization of colorectal cancer cells to irinotecan via the IAP antagonist BV6. | 2019 Aug |
4 |
| 14 |
29138869 | Cepharanthine exhibits a potent anticancer activity in p53-mutated colorectal cancer cells through upregulation of p21Waf1/Cip1. | 2018 Jan |
1 |
| 15 |
29257266 | Wee1 inhibition can suppress tumor proliferation and sensitize p53 mutant colonic cancer cells to the anticancer effect of irinotecan. | 2018 Feb |
1 |
| 16 |
29947891 | Sensitization of colorectal cancer cells to irinotecan by the Survivin inhibitor LLP3 depends on XAF1 proficiency in the context of mutated p53. | 2018 Aug |
1 |
| 17 |
29963241 | Survivin antagonizes chemotherapy-induced cell death of colorectal cancer cells. | 2018 Jun 12 |
1 |
| 18 |
29980405 | Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals. | 2018 Aug |
1 |
| 19 |
30085332 | Radiosensitization by irinotecan is attributed to G2/M phase arrest, followed by enhanced apoptosis, probably through the ATM/Chk/Cdc25C/Cdc2 pathway in p53-mutant colorectal cancer cells. | 2018 Oct |
3 |
| 20 |
30120489 | Replica to the Opinion Letter regarding the article "Sensitization of colorectal cancer cells to irinotecan by the Survivin inhibitor LLP3 depends on XAF1 proficiency in the context of mutated p53" (Arch Toxicol https://doi.org/10.1007/s00204-018-240-x). | 2018 Oct |
1 |
| 21 |
28000054 | 5-Flurouracil disrupts nuclear export and nuclear pore permeability in a calcium dependent manner. | 2017 Mar |
1 |
| 22 |
28131902 | CQ synergistically sensitizes human colorectal cancer cells to SN-38/CPT-11 through lysosomal and mitochondrial apoptotic pathway via p53-ROS cross-talk. | 2017 Mar |
6 |
| 23 |
25738310 | Sorafenib-irinotecan sequential therapy augmented the anti-tumor efficacy of monotherapy in hepatocellular carcinoma cells HepG2. | 2015 |
1 |
| 24 |
25833236 | Irinotecan induces cell cycle arrest, but not apoptosis or necrosis, in Caco-2 and CW2 colorectal cancer cell lines. | 2015 |
1 |
| 25 |
24968890 | Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-κB in vitro and in vivo. | 2014 Sep |
1 |
| 26 |
25064805 | Cytotoxicity and therapeutic effect of irinotecan combined with selenium nanoparticles. | 2014 Oct |
1 |
| 27 |
25474278 | Prognostic value of microsatellite instability and p53 expression in metastatic colorectal cancer treated with oxaliplatin and fluoropyrimidine-based chemotherapy. | 2014 Dec |
3 |
| 28 |
22721392 | The role of autophagic cell death and apoptosis in irinotecan-treated p53 null colon cancer cells. | 2013 Jun |
3 |
| 29 |
23373735 | Regulation of carboxylesterase-2 expression by p53 family proteins and enhanced anti-cancer activities among 5-fluorouracil, irinotecan and doxazolidine prodrug. | 2013 Apr |
1 |
| 30 |
23653048 | Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with irinotecan. | 2013 Jul |
2 |
| 31 |
22270257 | Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer. | 2012 Dec |
1 |
| 32 |
22647487 | MAPK14/p38α confers irinotecan resistance to TP53-defective cells by inducing survival autophagy. | 2012 Jul 1 |
1 |
| 33 |
22665525 | Pharmacogenomic profiling and pathway analyses identify MAPK-dependent migration as an acute response to SN38 in p53 null and p53-mutant colorectal cancer cells. | 2012 Aug |
4 |
| 34 |
22898888 | Irinotecan induces senescence and apoptosis in colonic cells in vitro. | 2012 Oct 2 |
1 |
| 35 |
20467885 | Simvastatin enhances irinotecan-induced apoptosis in human non-small cell lung cancer cells by inhibition of proteasome activity. | 2011 Oct |
1 |
| 36 |
21286718 | Cetuximab enhances the activities of irinotecan on gastric cancer cell lines through downregulating the EGFR pathway upregulated by irinotecan. | 2011 Oct |
1 |
| 37 |
21372224 | Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. | 2011 May 15 |
1 |
| 38 |
20164124 | Secreted protein acidic and rich in cysteine-induced cellular senescence in colorectal cancers in response to irinotecan is mediated by P53. | 2010 May |
1 |
| 39 |
18820127 | 90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1. | 2009 Jan |
1 |
| 40 |
18929442 | Inhibition of Akt signaling by SN-38 induces apoptosis in cervical cancer. | 2009 Feb 8 |
4 |
| 41 |
19491654 | Concomitant exposure of ovarian cancer cells to docetaxel, CPT-11 or SN-38 and adenovirus-mediated p53 gene therapy. | 2009 Aug |
4 |
| 42 |
19531575 | Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines. | 2009 Jul |
1 |
| 43 |
19653336 | Irinotecan therapy and molecular targets in colorectal cancer: a systemic review. | 2009 Aug 7 |
3 |
| 44 |
18381438 | The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner. | 2008 Apr 1 |
5 |
| 45 |
17255282 | CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo. | 2007 Jan 15 |
1 |
| 46 |
17487378 | The interactive transcript abundance index [c-myc*p73alpha]/[p21*Bcl-2] correlates with baseline level of apoptosis and response to CPT-11 in human bronchogenic carcinoma cell lines. | 2007 Jun |
1 |
| 47 |
17609585 | Irinotecan activates p53 with its active metabolite, resulting in human hepatocellular carcinoma apoptosis. | 2007 Jul |
7 |
| 48 |
17666793 | Irinotecan-induced apoptosis is inhibited by increased P-glycoprotein expression and decreased p53 in human hepatocellular carcinoma cells. | 2007 Aug |
5 |
| 49 |
17725105 | Schedule-dependent cytotoxicity of 5-fluorouracil and irinotecan in p53 mutant human colon cancer. | 2007 Jun |
2 |
| 50 |
16446370 | DNA damage-induced expression of p53 suppresses mitotic checkpoint kinase hMps1: the lack of this suppression in p53MUT cells contributes to apoptosis. | 2006 Mar 31 |
7 |